Moleculin Biotech (NASDAQ:MBRX) announced that it received a Notice of Intent to Grant from the European Patent Office (EPO) for its patent application covering Annamycin, a potential next-generation, non-cardiotoxic treatment for certain cancers.
According to the company, the forthcoming patent grant will bolster Annamycin’s global exclusivity, extending coverage to major markets beyond the U.S. The patent claims include methods for producing liposomal Annamycin suspension and the resulting compositions for use in cancer treatment, with protection extending through June 2040.
Moleculin is initiating the MIRACLE trial, a pivotal, adaptive Phase 3 study evaluating Annamycin in combination with cytarabine—together known as AnnAraC—for the treatment of relapsed or refractory acute myeloid leukemia.
In a statement, Wally Klemp, chairman and CEO of Moleculin, said, “Acknowledgement by the EPO of the innovation underlying Annamycin is an important milestone for Moleculin, underscoring the importance and proprietary nature of the innovation that makes this next generation anthracycline possible.”
“We expect Europe to be an important market for Annamycin and look forward to making an important new treatment available to patients in this region. The enhancing of our exclusivity for Annamycin is exciting when coupled with our continued expectation for an initial data readout for the MIRACLE trial in the second half of 2025,” he added.
